BioCardia Inc (BCDA)
2.38
-0.01
(-0.42%)
USD |
NASDAQ |
Nov 04, 16:00
BioCardia Research and Development Expense (Annual): 7.726M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.726M |
| December 31, 2022 | 8.834M |
| December 31, 2021 | 8.558M |
| December 31, 2020 | 9.809M |
| December 31, 2019 | 8.562M |
| December 31, 2018 | 8.453M |
| December 31, 2017 | 5.799M |
| December 31, 2016 | 3.33M |
| Date | Value |
|---|---|
| December 31, 2015 | |
| December 31, 2014 | |
| December 31, 2013 | |
| December 31, 2012 | |
| December 31, 2011 | |
| December 31, 2010 | |
| December 31, 2009 | |
| December 31, 2008 | 1.332M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
7.726M
Minimum
2023
9.809M
Maximum
2020
8.698M
Average
8.562M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Alnylam Pharmaceuticals Inc | 1.004B |
| Theriva Biologics Inc | 14.31M |
| Zevra Therapeutics Inc | 39.81M |
| PetIQ Inc | -- |
| Instil Bio Inc | 39.60M |